metricas
covid
Buscar en
Medicina Clínica
Toda la web
Inicio Medicina Clínica Exposición a fármacos modificadores de la enfermedad durante el embarazo en es...
Journal Information
Vol. 154. Issue 6.
Pages 214-217 (March 2020)
Share
Share
Download PDF
More article options
Visits
18
Vol. 154. Issue 6.
Pages 214-217 (March 2020)
Original breve
Exposición a fármacos modificadores de la enfermedad durante el embarazo en esclerosis múltiple: estudio prospectivo
Pregnancy exposure to disease-modifying drugs in multiple sclerosis: a prospective study
Visits
18
Juan Pablo Cuello
Corresponding author
juancuelloneuro@gmail.com

Autor para correspondencia.
, Paula Salgado Cámara, José Manuel García Domínguez, Alberto Lozano Ros, Miguel Mas Serrano, María Luisa Martínez Ginés
Servicio de Neurología, Hospital General Universitario Gregorio Marañón, Madrid, España
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (2)
Tabla 1. Datos demográficos generales y situación neurológica en pacientes con EM
Tabla 2. Resultados obstétricos de pacientes expuestas a FME
Show moreShow less
Resumen
Introducción

En esclerosis múltiple (EM), la exposición fetal a fármacos modificadores de la enfermedad (FME) conlleva distintos grados de riesgo. Objetivo: analizar nuestra experiencia en relación con los casos de exposición fetal involuntaria a FME.

Pacientes y métodos

Estudio observacional. Se analizaron los datos clínico-obstétricos de una cohorte de pacientes con EM, entre 2007 y 2017. Grupo EM: pacientes con EM con embarazos expuestos a FME. Grupo control: pacientes con EM no expuestas y embarazadas sanas.

Resultados

Hubo un total de 68 embarazos en pacientes con EM. Control: 56 mujeres sanas. Grupo EM expuestas a FME durante embarazo: 13; bajo peso al nacer: 2(15%); parto pretérmino: 0. Grupo EM no expuestas a FME: 55; 22 (40%) suspendieron FME previo embarazo; 33 (60%) naïve; bajo peso al nacer: 5 (9%); pretérmino: 7 (12%). Grupo mujeres sanas: bajo peso al nacer, 6 (11%); parto pretérmino, 6 (11%). No hubo diferencias clínicas estadísticamente significativas entre pacientes EM. Tampoco hubo diferencias en peso al nacer, tiempo de gestación o morbilidad obstétrica en expuestas a FME.

Conclusiones

No hubo diferencias clínicas estadísticamente significativas, ni mayor morbilidad obstétrica, entre pacientes expuestas a FME, no expuestas y embarazadas sanas.

Palabras clave:
Esclerosis múltiple
Embarazo
Fármacos modificadores enfermedad
Riesgo obstétrico
Tratamiento
Riesgo fetal
Abstract
Introduction

In multiple sclerosis (MS), foetal exposure to disease-modifying drugs (DMDs) carries varying degrees of risk. We sought to analyse the clinical and obstetric outcomes of MS patients (MSp) exposed to DMDs during pregnancy.

Patients and methods

Observational study. We analysed the clinical-obstetric data of a cohort MSp, who became pregnant between 2007-2017. They were prospectively followed up during pregnancy and postpartum. Control group: healthy pregnant women (HPW) and MSp unexposed to DMDs.

Results

Sixty-eight pregnancies in MSp. Fifty-six HPW. Thirteen MSp were exposed to DMDs during pregnancy. Obstetric outcome: 2 (15%) infants had low birth weight, no preterm deliveries. Fifty-five MSp were not exposed to DMDs: 22 (40%) discontinued DMD before pregnancy, 33(60%) naïve. Five infants (9%) had low birth weight and 7 (12%) were preterm. HPW: 56. Low birth weight 6 (11%), preterm delivery 6 (11%). There were no differences in relapse incidence during pregnancy-puerperium between MSp groups. There were no differences in birth weight, gestation time, delivery-caesarean section. We found no special obstetric morbidity in women exposed to DMDs.

Conclusions

There were no significant differences in the clinical and obstetric variables analysed between pregnant women exposed to DMDs, unexposed, and HPW.

Keywords:
Multiple sclerosis
Pregnancy
Disease modifying treatment
Obstetric Risk
Treatment
Foetal risk

Article

These are the options to access the full texts of the publication Medicina Clínica
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.medcli.2020.02.009
No mostrar más